Genetic abnormalities of somatostatin receptors in pituitary tumors.
Somatostatin exerts antisecretive and antiproliferative effects on different endocrine cells by acting through a family of G protein-coupled receptors that includes five subtypes (SST1-5). Normal human pituitary and pituitary adenomas have been shown to express almost all SST subtypes, with the exception of SST4. Consistent with the observation that octreotide and other somatostatin analogs bind to SST2 and SST5 with high affinity, these genes have been screened for quantitative/qualitative abnormalities in tumors removed from patients with poor responsiveness to somatostatin analogs treatment. Data obtained in GH-secreting adenomas suggested that resistance to octreotide was frequently associated with low expression of SST2 mRNA, although other authors failed to confirm this finding. To date, the only mutational change involving SST2 and SST5 is the Arg to Trp substitution in codon 240 of the SST5 gene that was found in one acromegalic patient resistant to octreotide. Similarly, loss of heterozygosis at SST5 gene locus in pituitary adenomas has been described in individual tumors. In recent years, molecular studies investigated the possible association of gene polymorphisms and susceptibility to diseases and/or resistance to drugs. As far as polymorphic variants of SST genes are concerned, a possible role of SST5 C1004T and T-461C alleles in influencing GH and IGF-I levels in patients with acromegaly has been proposed. Nevertheless, polymorphic variants in SST2 and SST5 genes seem to have a minor, if any, role in determining the different responsiveness to somatostatin analogs in patients with acromegaly.
Lania
A
A
Department of Medical Sciences, University of Milan, Fondazione Ospedale Maggiore IRCCS, Milan, Italy.
Mantovani
G
G
Spada
A
A
D000172:Acromegaly / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D000236:Adenoma / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D019656:Loss of Heterozygosity; D009154:Mutation; D015282:Octreotide / Q000627:therapeutic use; D010902:Pituitary Gland / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D011110:Polymorphism, Genetic; D017481:Receptors, Somatostatin / Q000235:genetics* / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D019382:Human Growth Hormone; D015282:Octreotide